Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Avient Corporation (AVNT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Avient CorporationTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Avient Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Avient Corporation trades at $45.09 (market cap $4.17B), while State Street SPDR S&P Biotech ETF trades at $158.95. The key difference: Avient Corporation pays a 2.42% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.

AVNTXBI
Market Cap
$4.17B
Sector
TechnologyBroad Market / Factor
52-Week High
$45.69$164.28
52-Week Low
$27.48$86.92
Enterprise Value
$5.62B
Dividend Yield
2.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Avient Corporation

Avient (AVNT) trades at $44.80, down 1.86% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates solid fundamentals with Q2 2026 EPS of $0.96 beating expectations by $0.07, marking the third consecutive earnings beat. Revenue growth of 5.8% to $917 million in Q2 2026 and improved net income margin of 5.1% reflect operational strength. Analyst consensus remains positive with 60% buy ratings and a $49.00 price target representing 9.4% upside potential.

Avient presents a favorable investment case with consistent earnings outperformance and positive analyst sentiment. The stock offers dividend income with recent $0.28 quarterly payments. Key risks include potential margin pressure from input costs and market volatility. Technical indicators show near-term overbought conditions with RSI at 78.87, suggesting possible consolidation before further upside toward the $49 consensus target.

State Street SPDR S&P Biotech ETF

XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.

The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.

Returns comparison

Trailing returns across standard periods

About Avient Corporation

Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.

Read more on AVNT

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI